BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Strategic Partnership with IBN

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced that it has joined forces with IBN, a leading financial news and publishing company, to enhance HYLK shareholder communication and spotlight the company’s unique technologies for improving healthcare. The collaboration is set to enhance HealthLynked’s corporate communication efforts and elevate its visibility within the investment community. As part of the client partner relationship, IBN will utilize its extensive investor-based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for HealthLynked. “It is critical for HealthLynked to increase our visibility among investors to support our mission of transforming healthcare through innovative technology. This partnership with IBN is a pivotal step towards realizing that vision,” said Dr. Michael Dent, CEO of HealthLynked.

To view the full press release, visit https://ibn.fm/ON9XS

About HealthLynked Corp.

HealthLynked is committed to revolutionizing healthcare on a global scale. Its mission is twofold: to transform the healthcare landscape into a system characterized by exceptional efficiency and superior patient care, and to cultivate a patient-centric network that places individuals at the forefront of their health management. By integrating cutting-edge technology and fostering connectivity, HealthLynked enables patients not just to participate in their healthcare journey, but also to contribute actively to medical research. This innovative approach facilitates the development of treatments for life-altering diseases and accelerates medical breakthroughs.

The company’s network empowers patients with unprecedented control over their medical data, promoting an environment of collaboration where each contribution has the potential to drive significant advancements in health and wellness. Through this pioneering model, HealthLynked is dedicated to securing a healthier future for generations to come, making each patient not only a beneficiary of this system but also a contributor to the global health community.

NOTE TO INVESTORS: The latest news and updates relating to HealthLynked are available in the company’s newsroom at https://IBN.fm/HLYK

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial

Lantern Pharma (NASDAQ: LTRN) announced that its wholly owned subsidiary, Starlight Therapeutics, has received FDA…

8 hours ago

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) to Report Q2 2025 Financial Results on August 14

NextPlat (NASDAQ: NXPL, NXPLW) a global provider of healthcare and technology solutions, will release its financial…

11 hours ago

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Market Demand for Breast CT Imaging Innovation 

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) emphasized the global trends driving demand for advanced…

1 day ago

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Canaccord 45th Annual Growth Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as ALS…

1 day ago

BioMedNewsBreaks — Soligenix, Inc. (NASDAQ: SNGX) Spotlighted in Editorial on Rare Disease Therapeutics 

Soligenix (NASDAQ: SNGX) has been featured in a NetworkNewsWire editorial highlighting its progress in addressing…

1 day ago

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride from Ketamine Products

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed a Citizen Petition with the…

2 days ago